Table 5.
Clinical features analysed for the patients receiving carbapenem or other AIT between day > 0 and day 30
| Missing data | Carbapenems n = 202 | Other AIT n = 364 | p value | |
|---|---|---|---|---|
| Severity criteria on admission | ||||
| SOFA score, median [IQR] | 4/8 | 5 [3–7] | 5 [3–6] | NS |
| Respiratory failure*, n (%) | 0 | 74 (37) | 123 (34) | NS |
| Cardiovascular failure*, n (%) | 0 | 79 (39) | 118 (32) | NS |
| Renal failure*, n (%) | 0 | 39 (19) | 77 (21) | NS |
| Septic shock, n (%) | 0 | 45 (22) | 65 (18) | NS |
| Acute respiratory distress syndrome, n (%) | 0 | 27 (13) | 25 (7) | < 0.05 |
| Main treatments between day > 0 and day 30 | ||||
| Need for red blood cell transfusion, n (%) | 0 | 87 (43) | 104 (29) | < 0.001 |
| Number of days of mechanical ventilation | 5/5 | 12 [2–26] | 2 [0–10] | < 0.001 |
| Vasoactive support, n (%) | 0/1 | 147 (73) | 184 (51) | < 0.001 |
| Renal replacement therapy, n (%) | 0/1 | 82 (41) | 94 (26) | < 0.001 |
| Duration of RRT, days, median [IQR] | 6/5 | 10 [3–22] | 5 [2–13] | < 0.01 |
| Main complications between day > 0 and day 30 | ||||
| Acute respiratory distress syndrome, n (%) | 1/1 | 101 (50) | 100 (28) | < 0.001 |
| Septic shock, n (%) | 15/31 | 102 (55) | 106 (32) | < 0.001 |
| Pancreatic necrosis, n (%) | 4/14 | 156 (79) | 229 (65) | < 0.001 |
| Infected necrosis, n (%) | 8/20 | 96 (49) | 100 (29) | < 0.001 |
| Gastro-intestinal perforation, n (%) | 12/18 | 23 (12) | 27 (8) | NS |
| Vascular thrombosis, n (%) | 9/16 | 36 (19) | 47 (14) | NS |
| Acute mesenteric ischaemia, n (%) | 10/17 | 26 (14) | 36 (10) | NS |
| Intra-abdominal collection, n (%) | 6/15 | 105 (54) | 131 (38) | < 0.001 |
| Abdominal compartment syndrome, n (%) | 9/17 | 33 (17) | 32 (9) | < 0.01 |
| Haemorrhage, n (%) | 8/18 | 44 (23) | 35 (10) | < 0.001 |
| Peritonitis, n (%) | 11/19 | 36 (19) | 47 (14) | NS |
| Cholangitis, n (%) | 8/17 | 18 (9) | 39 (11) | NS |
| Digestive fistula, n (%) | 10/18 | 11 (6) | 19 (5) | NS |
| Clinical management between day > 0 and day 30 | ||||
| Endoscopic necrosectomy, n (%) | 1/5 | 76 (38) | 71 (20) | < 0.001 |
| Surgical necrosectomy, n (%) | 1/5 | 94 (47) | 123 (34) | < 0.01 |
| Radiological drainage, n (%) | 1/5 | 63 (31) | 56 (16) | < 0.001 |
| Main reasons for anti-infective therapy between day > 0 and day 30 | ||||
| Intra-abdominal infection, n (%) | 11/13 | 153 (80) | 194 (55) | < 0.001 |
| Pneumonia, n (%) | 11/14 | 79 (41) | 89 (25) | < 0.001 |
| Bacteraemia, n (%) | 10/15 | 60 (31) | 76 (22) | < 0.05 |
| Anti-infective therapy administered between day > 0 and day 30 | ||||
| Duration of AIT, days, median [IQR] | 8/16 | 10 [3–17] | 5 [2–10] | < 0.001 |
| Aminoglycosides, n (%) | 4/19 | 129 (65) | 118 (34) | < 0.001 |
| Anti-Gram-positive agents, n (%) | 10/23 | 101 (53) | 60 (18) | < 0.001 |
| Antifungal agents, n (%) | 0/2 | 54 (27) | 56 (15) | < 0.01 |
| Azoles, n (%) | 6/2 | 32 (16) | 35 (10) | < 0.05 |
| Echinocandins, n (%) | 6/2 | 24 (12) | 20 (6) | < 0.01 |
| Duration of ICU stay, days, median [IQR] | 0 | 22 [9–39] | 8 [3–19] | < 0.001 |
| ICU readmission n (%) | 1/0 | 21 (10) | 29 (8) | NS |
| Hospital mortality rate, n (%) | 0 | 64 (32) | 77 (21) | < 0.01 |
| Time to death, days, median [IQR] | 0 | 29 [11–45] | 4 [1–18] | < 0.001 |
NS non-significant, NA not applicable, ERCP endoscopic retrograde cholangiopancreatography
*According to the definition of the SOFA score